Correlation Between Tae Kyung and AptaBio Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Tae Kyung and AptaBio Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Tae Kyung and AptaBio Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Tae Kyung Chemical and AptaBio Therapeutics, you can compare the effects of market volatilities on Tae Kyung and AptaBio Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Tae Kyung with a short position of AptaBio Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Tae Kyung and AptaBio Therapeutics.

Diversification Opportunities for Tae Kyung and AptaBio Therapeutics

0.4
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Tae and AptaBio is 0.4. Overlapping area represents the amount of risk that can be diversified away by holding Tae Kyung Chemical and AptaBio Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on AptaBio Therapeutics and Tae Kyung is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Tae Kyung Chemical are associated (or correlated) with AptaBio Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of AptaBio Therapeutics has no effect on the direction of Tae Kyung i.e., Tae Kyung and AptaBio Therapeutics go up and down completely randomly.

Pair Corralation between Tae Kyung and AptaBio Therapeutics

Assuming the 90 days trading horizon Tae Kyung Chemical is expected to generate 0.53 times more return on investment than AptaBio Therapeutics. However, Tae Kyung Chemical is 1.89 times less risky than AptaBio Therapeutics. It trades about 0.02 of its potential returns per unit of risk. AptaBio Therapeutics is currently generating about -0.03 per unit of risk. If you would invest  1,097,000  in Tae Kyung Chemical on September 22, 2024 and sell it today you would earn a total of  3,000  from holding Tae Kyung Chemical or generate 0.27% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Tae Kyung Chemical  vs.  AptaBio Therapeutics

 Performance 
       Timeline  
Tae Kyung Chemical 

Risk-Adjusted Performance

3 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Tae Kyung Chemical are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite somewhat strong basic indicators, Tae Kyung is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.
AptaBio Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days AptaBio Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Tae Kyung and AptaBio Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Tae Kyung and AptaBio Therapeutics

The main advantage of trading using opposite Tae Kyung and AptaBio Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Tae Kyung position performs unexpectedly, AptaBio Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AptaBio Therapeutics will offset losses from the drop in AptaBio Therapeutics' long position.
The idea behind Tae Kyung Chemical and AptaBio Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.

Other Complementary Tools

Commodity Directory
Find actively traded commodities issued by global exchanges
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
CEOs Directory
Screen CEOs from public companies around the world
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Insider Screener
Find insiders across different sectors to evaluate their impact on performance